Showing 1421-1430 of 1491 results for "".
- Novan's SB204 Demonstrates Positive Phase 2b Clinical Trial Results for the Treatment of Acne Vulgarishttps://practicaldermatology.com/news/novans-sb204-demonstrates-positive-phase-2b-clinical-trial-results-for-the-treatment-of-acne-vulgaris/2458863/Novan Therapeutics topical nitric oxide drug candidate SB204 for the treatment of acne vulgaris, demonstrated statistically significant reductions in the percent change of non-inflammatory (white heads and black heads) and
- New National Psoriasis Foundation Program Prioritizes Psoriatic Arthritishttps://practicaldermatology.com/news/20140626-new_national_psoriasis_foundation_program_prioritizes_psoriatic_arthritis/2459186/According to the National Psoriasis Foundation (NPF), millions of Americans with psoriatic arthritis struggle to get the health care and treatments they need to manage their condition. To help change that, the NPF launched the largest realignment and expansion of its psoriatic a
- Data Suggest Makucell's Asymmtate Reverses Gene Expression in Aging Skinhttps://practicaldermatology.com/news/20120725-makucell_announces_results_on_proprietary_technology_asymmtate/2459765/Makucell, Inc.'s Asymmtate(TM), the key ingredient in the Renewnt line, may reverse gene expression changes associated with aging skin and with lentigines. Findings for Asymmtate, a proprietary cosmetic ingredient that influences the gene co-act
- PN Therapeutic Pipeline Continues to Show Promisehttps://practicaldermatology.com/news/PN-Therapeutic-Pipeline-Continues-Show-Promise/2471649/The US Food and Drug Administration (FDA) approval last year of nemolizumab for the treatment of adults with prurigo nodularis (PN) was likely only the beginning of a dramatically changing therapeutic landscape for that condition, Sonja Stander, MD, IFAAD, said at the 2025 American Academy of Der
- Treating Hyperpigmented/Hypertrophic Scars with Microneedling in Skin of Colorhttps://practicaldermatology.com/news/Treating-Hyperpigmented-Hypertrophic-Scars-Microneedling-Skin-Color/2471641/Robyn Siperstein, MD, FAAD, presented “Use of Microneedling in Skin of Color: Treating Hyperpigmented and Hypertrophic Scars” at the 2025 American Academy of Dermatology Annual Meeting Sunday. “The key to this treatment and how I’ve really changed my anti-aging treatments are two things: O
- JAK Inhibitors, Low-Dose Naltrexone Touted as New Options for Nail Lichen Planushttps://practicaldermatology.com/news/JAK-Inhibitors-Low-Dose-Naltrexone-Touted-New-Options-Nail-Lichen-Planus/2471532/JAK inhibitors and low-dose naltrexone appear to be two game-changing options for treatment of nail lichen planus, Shari Lipner, MD, PhD, FAAD, said at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. Dr. Lipner noted the activity of the JAK pathway in lic
- Analysis: Fibrosis Mechanisms in Systemic Sclerosis Skinhttps://practicaldermatology.com/news/fibrosis-mechanisms-ssc-skin/2470860/Researchers have identified a shift toward reticular gene expression in systemic sclerosis (SSc) skin, with disruptions in WNT/β-catenin signaling playing a key role in these changes. Authors for the study, published in Arthritis and Rheumatology, analyzed skin morphology and mole
- Daily Imaging Boosts NMSC Treatment Success: Analysishttps://practicaldermatology.com/news/daily-imaging-boosts-nmsc-treatment-success-analysis/2468003/Image-guided superficial radiation therapy (IGSRT) was associated with a 99% cure rate for non-melanoma skin cancer (NMSC) when delivered with daily imaging, which allows for adaptive changes based on tumor depth fluctuations. Researchers for a recent retrospective study looked at the rol
- Quitting Smoking Reduces Hidradenitis Suppurativa Riskhttps://practicaldermatology.com/news/quitting-smoking-reduces-hidradenitis-suppurativa-risk/2467901/A new study suggests that smoking cessation is associated with reduced risk of developing hidradenitis suppurativa (HS). Researchers for the population-based cohort study looked at the relationship between the change in smoking habits and the incidence of HS in more than 6 million partic
- RINVOQ (Upadacitinib) Meets Primary Endpoint in Phase 2 Clinical Trial of Vitiligo, Program Advances to Phase 3https://practicaldermatology.com/news/upadacitinib-rinvoq-meets-primary-endpoint-in-phase-2-clinical-trial-of-vitiligo-program-advances-to-phase-3/2462064/Abbvie's upadacitinib (RINVOQ) met the primary endpoint of percent change from baseline in Facial Vitiligo Area Scoring Index (F-VASI) at week 24 with 11 mg and 22 mg doses versus placebo in adults with non-segmental vitiligo (NSV), according to data presented at the European Academy of Derma